A ten-year review of ESBL and non-ESBL Escherichia coli bloodstream infections among children at a tertiary referral hospital in South Africa

PLoS One. 2019 Sep 24;14(9):e0222675. doi: 10.1371/journal.pone.0222675. eCollection 2019.

Abstract

Introduction: There are few studies describing Escherichia coli (E. coli) bloodstream infection (BSI) among children in Africa, yet E.coli is increasing in importance as a cause of antibiotic resistant infection in paediatric settings.

Methods: In this retrospective, descriptive study aspects of E. coli BSI epidemiology are described over a 10-year period including incidence risk, risk factors for extended-spectrum β-lactamase (ESBL)-producing E. coli BSI, antibiotic susceptibility of the bacterial isolates and outcome including risk factors for severe disease.

Results: There were 583 new E. coli BSI episodes among 217,483 admissions, an overall incidence risk of 2.7 events/1,000 hospital admissions. Of 455 of these E. coli BSI episodes that were analysed, 136 (29.9%) were caused by ESBL-producing isolates. Risk factors for ESBL-producing E. coli BSI included hospitalization in the 28-day period preceding E. coli BSI episodes, having an underlying chronic illness other than HIV infection at the time of the E. coli BSI and having a temperature of 38° Celsius or higher at the time of the E. coli BSI. None of the E. coli isolates were resistant to carbapenems or colistin. The mortality rate was 5.9% and admission to the intensive care unit was required in 12.3% of BSI episodes. Predictors of severe disease included age less than 1 month, hospitalization in the 28-day period preceding E. coli BSI and BSI without a definable focus.

Conclusions: These findings extend our understanding of E. coli BSI in a sub-Saharan African setting, provide useful information that can guide empiric treatment choices for community- and hospital-acquired BSI and help inform prevention strategies.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Bacterial Agents / therapeutic use
  • Bacteremia / drug therapy
  • Bacteremia / epidemiology*
  • Child
  • Child, Preschool
  • Escherichia coli / drug effects*
  • Escherichia coli Infections / drug therapy
  • Escherichia coli Infections / epidemiology*
  • Female
  • Humans
  • Infant
  • Male
  • Microbial Sensitivity Tests
  • Retrospective Studies
  • Risk Factors
  • South Africa / epidemiology
  • Tertiary Care Centers / statistics & numerical data*
  • beta-Lactam Resistance*

Substances

  • Anti-Bacterial Agents

Grants and funding

There was no special funding for this work, except patient folders and clinical records and staff input from the Red Cross Hospital Children's Hospital - Paediatric infectious Diseases unit and University of Cape Town.